Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM2 Nivolumab + Entinostat in pediatric refractory high-risk solid and CNS tumors
NL-OMON55442Phase 2Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and entinostat in Nonhematologic neoplasms, refractory central nervous system tumor, central nervous system tumor and 1 more (8 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Dose limiting toxicity and Best response. Started Jul 2020; status: recruiting.
02
Drugs
nivolumabentinostat
03
Conditions
Nonhematologic neoplasmsrefractory central nervous system tumorcentral nervous system tumorglioma
Beyond the preview
Go deeper on NL-OMON55442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55442.